Additionally, high SEC62 expression was associated with a significantly shorter overall survival in HNSCC (Wemmert et al., 2016; Bochen et al., 2017), breast cancer (Takacs et al., 2019), and NSCLC (Linxweiler et al., 2013), a significantly shorter progression-free survival (PFS) in melanoma (Müller et al., 2021) and HNSCC (Wemmert et al., 2016) as well as a shorter recurrence-free survival in hepatocellular carcinoma (Weng et al., 2012; Du et al., 2019). Here, SEC62 is linked to non-small cell lung carcinoma.